A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

Part of paid clinical trials in San Francisco, California.

Sponsor
Priovant Therapeutics, Inc.
Study ID
NCT06978725
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Cutaneous Sarcoidosis

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Oral Brepocitinib — DRUG
    Drug: Oral Brepocitinib
  • Oral Placebo — DRUG
    Drug: Oral Placebo

Study Details

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Key Dates

Start date
Apr 9, 2025
Status verified
May 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
28 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Brepocitinib Dose Level 1
  • Experimental: Brepocitinib Dose Level 2
  • Placebo Comparator: Placebo

Primary Outcome Measure

Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0 [ Time Frame: Screening up to 28 days after the last dose of study drug at 16 weeks ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Clinical Trial SiteSan FranciscoCalifornia94115-
Clinical Trial SiteDurhamNorth Carolina27703-
Clinical Trial SitePhiladelphiaPennsylvania19104-
Clinical Trial SiteMadisonWisconsin53715-

Find similar trials in San Francisco, CA

By research site
Clinical Trial Site· San Francisco, CAClinical Trial Site· Durham, NCClinical Trial Site· Philadelphia, PAClinical Trial Site· Madison, WI